1887

Abstract

The Epstein–Barr virus (EBV) plays a key role in the development of undifferentiated nasopharyngeal carcinoma (uNPC). In uNPC endemic regions EBV-specific antibodies and plasma EBV DNA load are used as markers for the early detection of uNPC and monitoring of the disease. In non-endemic regions, such studies were practically not conducted. The aim of this study was to compare the clinical significance of EBV serological markers and plasma EBV DNA levels for uNPC patients in a non-endemic region, Russia. The results obtained indicate that both viral capsid antigen/immunoglobulin A (VCA/IgA) antibodies and plasma EBV DNA copies can effectively be used for nasopharyngeal carcinoma (NPC) diagnosis. Besides, plasma EBV DNA load was found to be a more sensitive marker of uNPC than VCA/IgA antibody titres, as it reflected the effect of the therapy in stages of remission and relapse of the disease more precisely. Our study, for the first time, demonstrates that the simultaneous use of plasma EBV DNA loads and VCA/IgA antibody levels are indispensable markers for uNPC in non-endemic regions: a serological marker can be more effectively used for NPC screening, but EBV DNA copies are better for monitoring the disease. However, both markers turned out to be practically unsuitable for assessing the clinical status of patients. Serological markers did not correlate with any signs of the tumour process estimated by tumour, node and metastasis (TNM) classification and the plasma EBV DNA loads correlated only with the size of the pathologically altered lymph nodes (N). Additional study is required to confirm these findings.

Keyword(s): EBV serology , NPC and plasma DNA EBV
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000889
2017-08-08
2019-09-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/8/2118.html?itemId=/content/journal/jgv/10.1099/jgv.0.000889&mimeType=html&fmt=ahah

References

  1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757–768 [CrossRef][PubMed]
    [Google Scholar]
  2. Gu AD, Zeng MS, Qian CN. The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation. Int J Mol Sci 2012;13:13737–13747 [CrossRef][PubMed]
    [Google Scholar]
  3. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res 2009;143:209–221 [CrossRef][PubMed]
    [Google Scholar]
  4. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:421–429[PubMed][CrossRef]
    [Google Scholar]
  5. Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazzé S et al. Cancer of the nasopharynx. Crit Rev Oncol Hematol 2003;45:199–214 [CrossRef][PubMed]
    [Google Scholar]
  6. Davydov MI, Axel EM. Statistics of malignant tumours in Russia and CIS countries in 2013. In: Journal of N.N. Blokhin Russian Cancer Research Center, Ministry of Health Moscow: Publishing Group of the Russian Cancer Center; 2015
    [Google Scholar]
  7. Barnes L, Eweson JW, Reichart P, Sidransky D. (editors) Pathology and Genetics Head and Neck Tumors Lyon: IARC Press; 2005
    [Google Scholar]
  8. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006;1:23 [CrossRef][PubMed]
    [Google Scholar]
  9. Luo S, Zhao L, Wang J, Xu M, Li J et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck 2014;36:841–847 [CrossRef][PubMed]
    [Google Scholar]
  10. Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007;6:1 [CrossRef][PubMed]
    [Google Scholar]
  11. Hubert A, De-Thé G. Dietary behavior, way of life, and nasopharyngeal cancer. Bull Cancer 1982;69:476–482[PubMed]
    [Google Scholar]
  12. Li J, Qian CN, Zeng YX. Regulatory T cells and EBV associated malignancies. Int Immunopharmacol 2009;9:590–592 [CrossRef][PubMed]
    [Google Scholar]
  13. Li X, Fasano R, Wang E, Yao KT, Marincola FM. HLA associations with nasopharyngeal carcinoma. Curr Mol Med 2009;9:751–765 [CrossRef][PubMed]
    [Google Scholar]
  14. Tsao SW, Tsang CM, To KF, Lo KW. The role of Epstein-Barr virus in epithelial malignancies. J Pathol 2015;235:323–333 [CrossRef][PubMed]
    [Google Scholar]
  15. Yeung WM, Zong YS, Chiu CT, Chan KH, Sham JS et al. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer 1993;53:746–750 [CrossRef][PubMed]
    [Google Scholar]
  16. Gurtsevitch V, Ruiz R, Stepina V, Plachov I, Le Riverend E et al. Epstein-Barr viral serology in nasopharyngeal carcinoma patients in the USSR and Cuba, and its value for differential diagnosis of the disease. Int J Cancer 1986;37:375–381 [CrossRef][PubMed]
    [Google Scholar]
  17. Pearson GR. Epstein-Barr virus and nasopharyngeal carcinoma. J Cell Biochem Suppl 1993;17F:150–154 [CrossRef][PubMed]
    [Google Scholar]
  18. Ho HC, Ng MH, Kwan HC. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br J Cancer 1978;37:356–362[PubMed][CrossRef]
    [Google Scholar]
  19. Song C, Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of nasopharyngeal carcinoma. Pak J Med Sci 2013;29:885–890[PubMed]
    [Google Scholar]
  20. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59:5452–5455[PubMed]
    [Google Scholar]
  21. Hou X, Zhao C, Guo Y, Han F, Lu LX et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol 2011;23:128–133 [CrossRef][PubMed]
    [Google Scholar]
  22. Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010;16:1016–1024 [CrossRef][PubMed]
    [Google Scholar]
  23. Chan KC, Chan AT, Leung SF, Pang JC, Wang AY et al. Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin Chem 2005;51:2192–2195 [CrossRef][PubMed]
    [Google Scholar]
  24. Fan H, Nicholls J, Chua D, Chan KH, Sham J et al. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 2004;112:1036–1041 [CrossRef][PubMed]
    [Google Scholar]
  25. Lo YM, Leung SF, Chan LY, Chan AT, Lo KW et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000;60:2351–2355[PubMed]
    [Google Scholar]
  26. Cao SM, Liu Z, Jia WH, Huang QH, Liu Q et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One 2011;6:e19100 [CrossRef][PubMed]
    [Google Scholar]
  27. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001;345:1877–1882 [CrossRef][PubMed]
    [Google Scholar]
  28. Kondo S, Horikawa T, Takeshita H, Kanegane C, Kasahara Y et al. Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients. Cancer Sci 2004;95:508–513 [CrossRef][PubMed]
    [Google Scholar]
  29. Leung SF, Tam JS, Chan AT, Zee B, Chan LY et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004;50:339–345 [CrossRef][PubMed]
    [Google Scholar]
  30. Shao JY, Zhang Y, Li YH, Gao HY, Feng HX et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res 2004;24:4059–4066[PubMed]
    [Google Scholar]
  31. Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007;67:130–137 [CrossRef][PubMed]
    [Google Scholar]
  32. Zhao FP, Liu X, Zhong ZM, Lu J, Yu BL et al. Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin a is a better prognostic biomarker for nasopharyngeal carcinoma. BBA Clin 2014;2:88–93 [CrossRef][PubMed]
    [Google Scholar]
  33. Chi KR. The tumour trail left in blood. Nature 2016;532:269–271 [CrossRef][PubMed]
    [Google Scholar]
  34. Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR. Circulating nucleic acids and apoptosis. Ann N Y Acad Sci 2001;945:239–249 [CrossRef][PubMed]
    [Google Scholar]
  35. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210–219 [CrossRef][PubMed]
    [Google Scholar]
  36. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 2006;94:1492–1495 [CrossRef][PubMed]
    [Google Scholar]
  37. Peng H, Chen L, Zhang Y, Guo R, Li WF et al. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Oncotarget 2016;7:24208–24216 [CrossRef][PubMed]
    [Google Scholar]
  38. Zhao FP, Liu X, Chen XM, Lu J, Yu BL et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma. Oncol Lett 2015;10:2888–2894 [CrossRef][PubMed]
    [Google Scholar]
  39. Chen WH, Tang LQ, Zhang L, Chen QY, Guo SS et al. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma. Oncotarget 2015;6:38296–38307 [CrossRef][PubMed]
    [Google Scholar]
  40. Chen WH, Tang LQ, Guo SS, Chen QY, Zhang L et al. Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era. Medicine 2016;95:e2642 [CrossRef][PubMed]
    [Google Scholar]
  41. Zhang Y, Li WF, Mao YP, Guo R, Tang LL et al. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma. Oncotarget 2016;7:9576–9585 [CrossRef][PubMed]
    [Google Scholar]
  42. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976;17:1–7 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000889
Loading
/content/journal/jgv/10.1099/jgv.0.000889
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error